Boston Scientific puts up $435m for Symetis just ahead of IPO

Boston Scientific (NYSE:BSX) is putting up $435 million in cash for Symetis and its line of minimally invasive replacement heart valves, the companies said today. The buyout halts the 2nd run at an initial public offering by Symetis, which launched the IPO March 20 in a bid to raise up to $66 million (€61.5 million) on the Euronext exchange in Paris. The Ecublens, Switzerland-based company, which acquired Middle Peak Medical and its transcatheter mitral valve implant just last month, spiked its 1st, $96 million IPO attempt in September 2015. Symetis employs about 300 workers worldwide. Boston Scientific said the Acurate transcatheter aortic valve implant developed by Symetis would complement its own Lotus TAVI program, which is under a voluntary recall while Boston addresses issues with its locking mechanism. (The Lotus platform is expected to return to market in the 4th quarter.) Symetis won CE Mark approval for the Acurate Neo device in 2014 and is running a clinical trial for the next-generation Acurate Neo/AS TAVI ahead of a bid for EU approval. “The steps we are taking reflect our commitment to being a leader in TAVI and structural heart technologies now and over the long-term, as we broaden our portfolio and pipeline to address the needs of our global health care providers and their patients,” global chief medical officer Dr. Ian Meredith said in prepared remarks. “The Acurate family of valve products is strongly complementary to ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Mergers & Acquisitions Replacement Heart Valves Wall Street Beat Boston Scientific Symetis Source Type: news